RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells

Endocrine-Related Cancer

Volumn 19, Issue 1, 2012, Pages 13-27

  Shan, B ^a   Gerez, J ^b   Haedo, M ^b   Fuertes, M ^b   Theodoropoulou, M ^a   Buchfelder, M ^c   Losa, M ^d   Stalla, G K ^a   Arzt, E ^b   Renner, U ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Faculty of Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN; PROTEIN RSUME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A; COBALT; HIF1A PROTEIN, HUMAN; RSUME PROTEIN, HUMAN; TRANSCRIPTION FACTOR; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOXIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN TRANSPORT; RNA INTERFERENCE; UPREGULATION; ADENOMA; ANIMAL; ANOXIA; BIOSYNTHESIS; GENETICS; HYPOPHYSIS TUMOR; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL CULTURE; TUMOR CELL LINE;

ADENOMA; ANIMALS; ANOXIA; CELL LINE, TUMOR; COBALT; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860335047     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0211     Document Type: Article

References (46)

1. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ & Gleadle JM 2004 Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. Journal of Biological Chemistry 279 38458-38465. (doi:10.1074/jbc.M406026200)
2. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254. (doi:10.1016/0003-2697(76)90527-3)
3. Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F & Arzt E 2007 RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131 309-323. (doi:10.1016/j.cell.2007.07.044)
4. Carmeliet P 2003 Angiogenesis in health and disease. Nature Medicine 9 653-660. (doi:10.1038/nm0603-653)
5. Carmeliet P 2005 VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl 3) 4-10. (doi:10.1159/000088478)
6. Castro CP, Giacomini D, Nagashima AC, Onofri C, Graciarena M, Kobayashi K, Paez-Pereda M, Renner U, Stalla GK & Arzt E 2003 Reduced expression of the cytokine transducer gp130 inhibits hormone secretion, cell growth, and tumor development of pituitary lactosomatotrophic GH3 cells. Endocrinology 144 693-700. (doi:10.1210/en.2002-220891)
7. Chen HC, Sytwu HK, Chang JL, Wang HW, Chen HK, Kang BH, Liu DW, Chen CH, Chao TT & Wang CH 2011 Hypoxia enhances the stemness markers of cochlear stem/progenitor cells and expands sphere formation through activation of hypoxia-inducible factor-1 alpha. Hearing Research 275 43-52. (doi:10.1016/j.heares.2010.12.004)
8. Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, Wiesmann M, Garcia PD, Fuller JH, Chan V et al. 2003 β-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Research 63 3145-3153. (Pubitemid 36735866)
9. Ebert BL & Bunn HF 1999 Regulation of the erythropoietin gene. Blood 94 1864-1877. (Pubitemid 29430402)
10. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G & Semenza GL 1999 Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Research 59 3915-3918. (Pubitemid 29393552)
11. Ferrara N 2004 Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 25 581-611. (doi:10.1210/er.2003-0027)
12. Flugel D, Gorlach A, Michiels C & Kietzmann T 2007 Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Molecular and Cellular Biology 27 3253-3265. (doi:10.1128/MCB.00015-07)
13. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC & Harris AL 2001 Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. British Journal of Cancer 85 881-890. (doi:10.1054/bjoc.2001.2018)
14. Goldberg MA, Dunning SP & Bunn HF 1988 Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242 1412-1415. (doi:10.1126/science.2849206)
15. Harris AL 2002 Hypoxia - a key regulatory factor in tumour growth. Nature Reviews. Cancer 2 38-47. (doi:10.1038/nrc704)
16. Hickey MM & Simon MC 2006 Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Current Topics in Developmental Biology 76 217-257. (doi:10.1016/S0070-2153(06)76007-0)
17. 2-regulated prolyl hydroxylation. Science 292 468-472. (doi:10.1126/science.1059796)
18. Jugenburg M, Kovacs K, Stefaneanu L & Scheithauer BW 1995 Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocrine Pathology 6 115-124. (doi:10.1007/BF02739874)
19. Kim K, Yoshida D & Teramoto A 2005 Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocrine Pathology 16 115-121. (doi:10.1385/EP:16:2:115)
20. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P et al. 2003 Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Research 63 1138-1143. (Pubitemid 36278449)
21. Land SC & Tee AR 2007 Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. Journal of Biological Chemistry 282 20534-20543. (doi:10.1074/jbc.M611782200)
22. Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K & Levine AC 1999 Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clinical & Experimental Metastasis 17 687-694. (doi:10.1023/A:1006728119549)
23. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K &Stefaneanu L 1999 Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocrine Pathology 10 229-235. (doi:10.1007/ BF02738884)
24. Lohrer P, Gloddek J, Hopfner U, Losa M, Uhl E, Pagotto U, Stalla GK & Renner U 2001 Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 74 95-105. (doi:10.1159/000054675)
25. Masson N & Ratcliffe PJ 2003 HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. Journal of Cell Science 116 3041-3049. (doi:10.1242/jcs.00655)
26. Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A, Georgatsou E, Bonanou S &Simos G 2006 Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. Journal of Biological Chemistry 281 33095-33106. (doi:10.1074/jbc.M605058200)
27. Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T & Kerbel RS 1998 Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. PNAS 95 3609-3614. (doi:10.1073/pnas.95.7.3609)
28. Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK & Renner U 2006 Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. Journal of Endocrinology 191 249-261. (doi:10.1677/joe.1.06992)
29. Pagotto U, Arzberger T, Theodoropoulou M, Grubler Y, Pantaloni C, Saeger W, Losa M, Journot L, Stalla GK &Spengler D 2000 The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Research 60 6794-6799. (Pubitemid 32059140)
30. Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A, Lange M, Weindl A & Stalla GK 1998 Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 83 1368-1375. (doi:10.1210/jc.83.4.1368)
31. Schechter J 1972 Ultrastructural changes in the capillary bed of human pituitary tumors. American Journal of Pathology 67 109-126.
32. Shima DT, Deutsch U & D'Amore PA 1995 Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Letters 370 203-208. (doi:10.1016/0014- 5793(95)00831-S)
33. Steinbrech DS, Mehrara BJ, Saadeh PB, Greenwald JA, Spector JA, Gittes GK & Longaker MT 2000 VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. American Journal of Physiology. Cell Physiology 278 C853-C860. (Pubitemid 30211316)
34. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL & Wass JA 2000 Angiogenesis in pituitary adenomas and the normal pituitary gland. Journal of Clinical Endocrinology and Metabolism 85 1159-1162. (doi:10.1210/jc.85.3.1159)
35. Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I et al. 2003 Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. Journal of Endocrinological Investigation 26 23-28. (Pubitemid 36292248)
36. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T &Lloyd RV 2001 Microvessel density in pituitary adenomas and carcinomas. Virchows Archiv 438 595-602. (doi:10.1007/s004280000373)
37. Vidal S, Horvath E, Kovacs K, Kuroki T, Lloyd RV &Scheithauer BW 2003a Expression of hypoxia-inducible factor-1alpha (HIF-1alpha) in pituitary tumours. Histology and Histopathology 18 679-686. (Pubitemid 36773211)
38. Vidal S, Horvath E, Kovacs K, Lloyd RV & Scheithauer BW 2003b Microvascular structural entropy: a novel approach to assess angiogenesis in pituitary tumors. Endocrine Pathology 14 239-247. (doi:10.1007/s12022-003-0016- 0)
39. 2 tension. PNAS 92 5510-5514. (doi:10.1073/pnas.92.12.5510)
40. Webb JD, Coleman ML & Pugh CW 2009 Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cellular and Molecular Life Sciences 66 3539-3554. (doi:10.1007/s00018-009-0147-7)
41. Wei W & Yu XD 2007 Hypoxia-inducible factors: crosstalk between their protein stability and protein degradation. Cancer Letters 257 145-156. (doi:10.1016/j.canlet.2007.08.009)
42. Yamamoto H, Ihara M, Matsuura Y & Kikuchi A 2003 Sumoylation is involved in beta-catenin-dependent activation of Tcf-4. EMBO Journal 22 2047-2059. (doi:10.1093/emboj/cdg204)
43. Yoshida D, Kim K, Yamazaki M & Teramoto A 2005 Expression of hypoxia-inducible factor 1alpha and cathepsin D in pituitary adenomas. Endocrine Pathology 16 123-131. (doi:10.1385/EP:16:2:123)
44. Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS &Coomber BL 2001 Heterogeneous vascular dependence of tumor cell populations. American Journal of Pathology 158 1325-1334. (doi:10.1016/S0002-9440(10)64083-7)
45. Yuan Y, Hilliard G, Ferguson T & Millhorn DE 2003 Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. Journal of Biological Chemistry 278 15911-15916. (doi:10.1074/jbc.M300463200)
46. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL &Simons JW 1999 Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Research 59 5830-5835.